Furthermore, RBD has been highlighted as a strong precursor for future development of those neurodegenerative diseases over several years in prior, which seems to be a great opportunity for improving the treatments of the disease.Sleep disturbances have been also observed in Alzheimers disease (AD), affecting about 45% of its population. When based on caregiver reports, this percentage increases to about 70%. As well as in PD population, insomnia and hypersomnia are frequently recognized in AD patients, which have been associated with accumulation of beta-amyloid, circadian rhythm sleep disorders (CRSD) and melatonin alteration. Additionally, changes in sleep architecture are observed in AD. Although sleep architecture seems to naturally change with age, its development appears aggravated in AD patients. SWS potentially decreases (and is sometimes absent), spindles and the length of time spent in REM sleep are also reduced, while its latency increases. Poor sleep onset in AD has been associated with dream-related hallucination, increased restlessness, wandering and agitation that seem related to sundowning - a typical chronobiological phenomenon presented in the disease.The neurodegenerative conditions are commonly related to structural brain impairment, which might disrupt the states of sleep and wakefulness, circadian rhythm, motor or non motor functioning. On the other hand, sleep disturbances are frequently related to worsening patients cognitive functioning, emotional state and quality of life. Furthermore, these abnormal behavioral symptoms negatively contribute to overwhelming their relatives and caregivers. The limited research related to it and the increasing life expectancy calls for a deeper understanding of the relationship between sleep disorders and neurodegenerative disease.
Lathosterolosis is a defect in cholesterol biosynthesis. See also
SC5DL
Lathosterol

References


== External links ==